We examined the prevalence of HCV, hepatitis B virus (HBV), and HIV among non-injecting drug users (NIDUs) in community-based drug treatment (N = 122) and NIDUs in a prison-based drug treatment program (N = 30), both located in west central Mexico.
Among the community clients, prevalence was 4.1%(95%confidence interval [CI]: 1.8-9.2) for HCV, 5.7%for HBV (95%CI: 2.8-11.4), and 1.6%for HIV (95%CI: 0.4-5.8). Among the in-prison clients, prevalence was 40.0%(95%CI: 24.6-57.7) for HCV, 20.0%for HBV (95%CI: 9.5-37.3), and 6.7%for HIV (95%CI: 1.9-21.3). None of the clients were aware of being infected.
The HCV prevalence found for the NIDU community treatment clients ranks among the lower HCV estimates published for NIDUs in treatment to date. The prevalence found for the in-prison clients ranks among the higher, raising a concern of possible elevated HCV infection among NIDUs in the west central Mexico prison鈥攐ne compounded by the finding that none of this study's clients knew they were HCV positive.